8-K: Karyopharm Therapeutics Faces Default, Seeks Forbearance

Karyopharm Therapeutics Inc. has entered into a Forbearance Agreement and Limited Waiver to Indentures due to missed principal and interest payments, highlighting severe financial distress and potential going concern issues.

Summary

• Karyopharm Therapeutics Inc. (the Company) has entered into a Forbearance Agreement and Limited Waiver to Indentures with its lenders and noteholders.
• This agreement provides temporary relief from exercising rights and remedies related to specified defaults, including missed principal and interest payments.
• The Company failed to pay a principal installment of approximately $15.8 million due on September 10, 2026, and does not expect to pay cash interest due on September 30, 2026.
• These defaults, if not cured, could lead to cross-defaults under other agreements, including a Royalty Agreement.
• The Company is also at risk of not meeting a $25.0 million minimum liquidity covenant after October 10, 2026.
• As consideration for the forbearance, the Company will issue $20.0 million worth of 0% convertible perpetual preferred stock.
• The Company's existing liquidity is expected to fund operations only until October 15, 2026, after which it may face bankruptcy, liquidation, or cessation of operations without additional funding or strategic transactions.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this as a highly negative development due to the company's inability to meet its financial obligations and the significant risk of bankruptcy.

Positives

• The company has secured a forbearance agreement, providing a short window to negotiate with lenders, pursue strategic alternatives, or raise capital.
• The agreement temporarily prevents lenders and noteholders from exercising their full rights and remedies related to the specified defaults.
• The company has a clear, albeit short, timeline (until October 15, 2026) to secure additional funding or execute strategic transactions.

Negatives

• The company missed a principal payment of approximately $15.8 million and expects to miss an interest payment of approximately $2.8 million.
• The company is at risk of breaching a $25.0 million minimum liquidity covenant by October 10, 2026.
• Failure to secure additional funding or complete strategic transactions by October 15, 2026, could lead to bankruptcy, liquidation, or cessation of operations.
• The company will pay $20.0 million in fees, partly in the form of convertible preferred stock, increasing future dilution potential.
• Obligations under the Credit Agreement and Notes will bear an additional 2.00% per annum interest rate due to the defaults.

Risks

• Substantial doubt exists regarding the Company's ability to continue as a going concern.
• Without additional funding or strategic transactions by October 15, 2026, the Company may be forced to seek bankruptcy protection, liquidate assets, or cease operations.
• The Forbearance Agreement expires on October 15, 2026, or earlier upon certain events, after which all overdue amounts become immediately due and payable, and creditors can exercise remedies including acceleration.
• The FDA's refusal to accept the Company's supplemental New Drug Application (sNDA) for selinexor in combination with ruxolitinib for myelofibrosis is an event that can terminate the forbearance period.
• Competitors developing similar drug candidates could impact the Company's market position and future prospects.
• The Company's ability to enroll patients in clinical trials could be affected.
• Unplanned cash requirements and expenditures could exacerbate the liquidity crisis.

Future Outlook

The Company's existing liquidity is projected to fund current operating plans only until October 15, 2026. Without additional funding or successful strategic transactions, the Company faces significant risks, including potential bankruptcy, liquidation, or cessation of operations. The success of the myelofibrosis program and FDA review of the sNDA are critical factors.

Management Comments

• The Company expects that its existing liquidity, including cash, cash equivalents, and investments as well as cash flow from net product revenue and license and other revenue, will enable the Company to fund its current operating plans until October 15, 2026.
• Absent additional funding or entry into one or more strategic transactions to extend the Company's cash runway beyond October 15, 2026, the Company will be unable to continue as a going concern and may have to consider seeking protection under the bankruptcy laws, liquidating assets or ceasing operations.

Industry Context

StockSavvy.ai notes that this filing reflects a critical juncture for Karyopharm Therapeutics, common in the biotechnology sector where high R&D costs and long development timelines can lead to significant financial pressures. The company's reliance on a forbearance agreement and the potential for bankruptcy highlight the inherent risks in drug development and commercialization, especially when facing liquidity challenges and regulatory hurdles.

Stakeholder Impact

• Shareholders: Potential for significant dilution from the issuance of convertible preferred stock and the ultimate outcome of the company's financial distress, including potential bankruptcy which could render shares worthless.
• Creditors/Lenders: Risk of non-payment of principal and interest, with forbearance agreements providing only temporary relief; potential for acceleration of debt upon termination of forbearance.
• Employees: Uncertainty regarding continued employment if the company ceases operations or undergoes bankruptcy proceedings.
• Suppliers: Potential for delayed or non-payment of outstanding invoices if the company faces severe liquidity issues.

Next Steps

• The Company must secure additional funding or complete strategic transactions by October 15, 2026, to avoid bankruptcy or cessation of operations.
• The Company needs to obtain shareholder approval for the full conversion of the Convertible Preferred Stock by March 15, 2027.
• Lenders and noteholders may exercise their rights and remedies, including acceleration of debt, upon termination of the Forbearance Period.
• The Company will pay fees and expenses of the Consenting Parties' advisors.
• The Company will undertake to obtain shareholder consent for the full issuance of Common Stock upon conversion of the Convertible Preferred Stock.

Key Dates

Recommendation

The filing indicates severe financial distress, with the company missing debt payments and facing a substantial going concern risk. The short cash runway and potential for bankruptcy make the stock a high-risk investment, warranting a sell recommendation.

Keywords

Forbearance Agreement, Default, Liquidity, Going Concern, Convertible Preferred Stock, Credit Agreement, Convertible Senior Notes, Myelofibrosis